| Primary |
| Hodgkin's Disease |
61.7% |
| Hodgkin's Lymphoma |
9.7% |
| Hodgkin's Disease Refractory |
5.7% |
| Product Used For Unknown Indication |
3.7% |
| Hodgkin's Disease Recurrent |
3.0% |
| Diffuse Large B-cell Lymphoma |
2.7% |
| Lymphoma |
2.3% |
| Acute Graft Versus Host Disease |
2.0% |
| Anaplastic Large-cell Lymphoma |
1.3% |
| Non-hodgkin's Lymphoma |
1.3% |
| T-cell Lymphoma |
1.3% |
| Angioimmunoblastic T-cell Lymphoma |
1.0% |
| Mycosis Fungoides |
1.0% |
| Drug Use For Unknown Indication |
0.7% |
| Hodgkin's Disease Stage Iv |
0.7% |
| Hodgkin's Lymphoma |
0.3% |
| Acute Myeloid Leukaemia |
0.3% |
| Anaplastic Large Cell Lymphoma T- And Null-cell Types |
0.3% |
| Germ Cell Cancer |
0.3% |
| Lymphomatoid Papulosis |
0.3% |
|
| Vomiting |
14.1% |
| Febrile Neutropenia |
9.4% |
| Pyrexia |
9.4% |
| Sepsis |
9.4% |
| White Blood Cell Count Decreased |
8.2% |
| Pancreatitis |
7.1% |
| Pneumonia |
5.9% |
| Death |
3.5% |
| Stem Cell Transplant |
3.5% |
| Thrombocytopenia |
3.5% |
| Urticaria |
3.5% |
| Weight Decreased |
3.5% |
| Gastrointestinal Infection |
2.4% |
| Neutropenia |
2.4% |
| Oral Candidiasis |
2.4% |
| Pancytopenia |
2.4% |
| Platelet Count Decreased |
2.4% |
| Rash |
2.4% |
| Rash Maculo-papular |
2.4% |
| Sinus Tachycardia |
2.4% |
|
| Secondary |
| Hodgkin's Disease |
43.1% |
| Anaplastic Large-cell Lymphoma |
13.9% |
| Product Used For Unknown Indication |
11.1% |
| Anaplastic Large Cell Lymphoma T- And Null-cell Types |
8.3% |
| T-cell Prolymphocytic Leukaemia |
8.3% |
| Prophylaxis Against Graft Versus Host Disease |
4.2% |
| Chemotherapy |
2.8% |
| Lymphoma |
2.8% |
| Vasculitis Necrotising |
2.8% |
| Mycosis Fungoides Refractory |
1.4% |
| T-cell Lymphoma Recurrent |
1.4% |
|
| Diabetes Mellitus |
7.7% |
| Infusion Related Reaction |
7.7% |
| Oedema |
7.7% |
| Pneumonia |
7.7% |
| Pulmonary Toxicity |
7.7% |
| Pyrexia |
7.7% |
| Respiratory Failure |
7.7% |
| Therapeutic Product Ineffective |
7.7% |
| Thrombocytopenia |
7.7% |
| Transplant Rejection |
7.7% |
| Vasculitis Necrotising |
7.7% |
| Vomiting |
7.7% |
| Weight Decreased |
7.7% |
|
| Concomitant |
| Anaplastic Large Cell Lymphoma T- And Null-cell Types |
51.2% |
| Mycosis Fungoides |
46.5% |
| Chronic Lymphocytic Leukaemia Refractory |
2.3% |
|
| Sepsis |
66.7% |
| Vomiting |
33.3% |
|
| Interacting |
| Product Used For Unknown Indication |
51.1% |
| Hiv Infection |
12.8% |
| Antiemetic Supportive Care |
6.4% |
| Hodgkin's Disease |
6.4% |
| Prophylaxis |
6.4% |
| Blood Glucose Increased |
4.3% |
| Enzyme Inhibition |
4.3% |
| Haematological Malignancy |
4.3% |
| Antibiotic Prophylaxis |
2.1% |
| Gastrointestinal Disorder |
2.1% |
|
| Vomiting |
50.0% |
| Drug Interaction |
25.0% |
| Sepsis |
25.0% |
|
